{
  "docId": "019de075-03fc-75b4-9b20-1ad4baba72b2",
  "docSlug": "9cc11288f450409d9a3eef75fc694943",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 39,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "Uses a visual process flow to contrast existing therapy failure with Nuvalent's solution.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-03fc-75b4-9b20-1ad4baba72b2/7",
  "deckHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2",
  "deckJsonHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2.json",
  "deckAnchorHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.65,
        "x": 0.3,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Original tumor evolving into drug-resistant tumor via mutation",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e73b1f81-3fe2-479c-88e6-2404ce355054",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.65,
        "x": 0.3,
        "y": 0.5
      },
      "kind": "image",
      "text": "Comparison of existing vs Nuvalent therapy in normal and mutated kinase scenarios",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9db8511c-b190-4e1c-805d-5f48515291b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.07,
        "y": 0.52
      },
      "kind": "paragraph",
      "text": "Structural innovations designed to overcome drug-resistance due to kinase mutations",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3805f300-21a2-49d4-a8ac-a25a4974345c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.2,
        "x": 0.07,
        "y": 0.42
      },
      "kind": "title",
      "text": "Kinase Resistance",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "862f0fb8-710c-4b1e-b29b-351e966d6109",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "b5aa90f6-4e17-48bf-8efa-b81a1083d573",
      "evidence": "paragraph/paragraph: Structural innovations designed to overcome drug-resistance due to kinase mutations",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "before-after-bridge",
      "slug": null,
      "matchId": "55fb4430-7846-4478-bf58-a057ccf11fb7",
      "evidence": "Contrasts the state of existing therapy failure with the solution provided by Nuvalent.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 7,
      "from": 7,
      "beatId": "dce8d00e-e9e7-43e2-a3b4-5386c78907ab",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The document presents a clear problem statement on kinase resistance and selectivity challenges in cancer treatment.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 26,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "fe9c6514-22f1-4979-9b36-391b44fa3c8a",
      "evidence": "The document presents the limitations of current therapies and the potential benefits of Nuvalent's targeted therapies.",
      "position": 0,
      "objective": "The cost of inaction in addressing kinase resistance and selectivity challenges",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}